All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On Monday 3 December 2018, Oral Session 642 took place at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. During that session, results from the phase III iLLUMINATE (PCYC-1130) trial (Abstract #691) were presented by Carol Moreno from the Autonomous University of Barcelona, Barcelona, SP.
In this international, multicenter, randomized, phase III trial two combination regimens were investigated as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Ibrutinib and obinutuzumab combination was compared to chlorambucil and obinutuzumab for their efficacy and safety. This study is one of the first to compare a chemotherapy-free regimen to chemo-immunotherapy for CLL/SLL patients. The primary endpoint of the study was progression-free survival (PFS) as assessed by an Independent Review Committee (IRC). Secondary endpoints include overall response rate (ORR), overall survival (OS), safety, rate of undetectable minimal residual disease (MRD), and PFS by IRC in the high-risk population.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox